A Study of Hemopure® to Enhance Tissue Preservation During Cardiopulmonary Bypass Surgery

Inclusion Criteria: * Subject is between the ages of 18 and 80. * Subject is an acceptable candidate for CABG. * Subject is scheduled for CABG (without planned valvular repair or replacement) by cardiopulmonary bypass. * Subject signs informed consent * Subject and the treating physician agree that subject can comply with all study procedures and follow-up visit at time of subject screening. Exclusion Criteria: * Pre-operative myocardial infarction, defined as CK-MB level \> 2 times upper limit of normal 24 hours prior to CABG surgery. * Renal failure defined as serum creatinine greater 220 µmol/L * Subject has an ejection fraction ≤ 30% (as measured by Echocardiography within 30 days of study enrollment). * Active infection. * History of prior stroke within last six months or history of prior stroke with residual neurological deficit. * Transient Ischemic attack within last 6 months. * Subject has a history of coagulopathy. * Subject is pregnant or currently breastfeeding. * History of allergy to beef products. * Pre-operative cardiogenic shock defined as cardiac index ≤ 1.8.L/min/m2 despite the use of vasopressors. * Underlying medical conditions that would limit subject's life expectancy to less than 12 months. * Severe pulmonary disease \[based upon clinical diagnosis or pulmonary function tests (FEV \<1 liter), if available\] that may interfere with weaning subject from ventilator. * History of acute central nervous disorder (e.g., seizure or traumatic injury). * Severe hypertension (≥ 160/90 mm Hg) that cannot be medically controlled despite treatment with two antihypertensive therapies. * Severe liver dysfunction as defined by total bilirubin ≥ 51 µmol/L or 2 times the site normal limit of AST or ALT activity. * Subject has systemic mastocytosis. * Subject has any condition that predisposes the subject to systemic mast cell degranulation or hypersensitivity reactions or a history of severe allergic reactions to drugs or environmental allergens. * Subject has participated in another investigational drug, biologic or device study within 30 days prior to study enrollment.